TRDA · Entrada Therapeutics, Inc. · Analyst Estimates
$5.17
-0.27 (-4.96%)
At close · Nov 12
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of our recurring losses from operations and recurring negative cash flows from operations, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$202.41M
Shares
39.15M
Volume · Nov 12
808.67K
Avg daily vol (3M)
365.68K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Entrada Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-12 22:52 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-4.05
|
-3.95
|
-3.86
|
3
|
-3.93
|
-3.79
|
-3.70
|
-3.72
|
0
|
1
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
2.68M
|
2.99M
|
3.58M
|
3
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-4.16
|
-3.36
|
-2.90
|
4
|
-3.24
|
-3.01
|
-2.98
|
-3.28
|
0
|
1
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
3.58M
|
30.63M
|
50.00M
|
4
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.15
|
-1.05
|
-0.96
|
4
|
-0.98
|
-0.88
|
-0.87
|
-0.87
|
1
|
1
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
452,500.00
|
905,000.00
|
2
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.10
|
-0.75
|
-0.12
|
4
|
-0.75
|
-0.76
|
-0.75
|
-0.75
|
1
|
1
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
11.00M
|
28.00M
|
45.00M
|
2
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1689375
CUSIP
29384C108
13F (30d)
70 filings
57 filers
Visit website
Investor relations